Statins and outcome after hospitalization for COPD exacerbation: A prospective study

Pulmonary Pharmacology and Therapeutics

Volumn 24, Issue 5, 2011, Pages 625-631

  Bartziokas, Konstantinos ^a,b   Papaioannou, Andriana I ^a   Minas, Markos ^a   Kostikas, Konstantinos ^a   Banya, Winston ^c   Daniil, Zoe D ^a   Haniotou, Aikaterini ^b   Gourgoulianis, Konstantinos I ^a  

^a UNIVERSITY OF THESSALY   (Greece)

^b AMALIA FLEMING GENERAL HOSPITAL   (Greece)

^c ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Cardiovascular comorbidities; COPD; COPD exacerbations; Health related quality of life; Mortality; Statins

Indexed keywords

ANTIBIOTIC AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; ROSUVASTATIN; SALBUTAMOL; SIMVASTATIN; THEOPHYLLINE; TIOTROPIUM BROMIDE;

AGED; ARTICLE; BODY MASS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; CLINICAL EVALUATION; COMORBIDITY; DEATH; DISEASE EXACERBATION; DISEASE SEVERITY; FEMALE; FOLLOW UP; GENDER; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; SPIROMETRY; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; FEMALE; FOLLOW-UP STUDIES; HOSPITALIZATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; QUESTIONNAIRES; RISK; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 80052406894     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2011.06.003     Document Type: Article

References (36)

1. Rabe K.F., Hurd S., Anzueto A., Barnes P.J., Buist S.A., Calverley P., et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007, 176(6):532-555.
2. Soler-Cataluna J.J., Martinez-Garcia M.A., Roman Sanchez P., Salcedo E., Navarro M., Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005, 60(11):925-931.
3. Barnes P.J., Celli B.R. Systemic manifestations and comorbidities of COPD. Eur Respir J 2009, 33(5):1165-1185.
4. Young R.P., Hopkins R., Eaton T.E. Potential benefits of statins on morbidity and mortality in chronic obstructive pulmonary disease: a review of the evidence. Postgrad Med J 2009, 85(1006):414-421.
5. Soyseth V., Brekke P.H., Smith P., Omland T. Statin use is associated with reduced mortality in COPD. Eur Respir J 2007, 29(2):279-283.
6. Mortensen E.M., Copeland L.A., Pugh M.J., Restrepo M.I., de Molina R.M., Nakashima B., et al. Impact of statins and ACE inhibitors on mortality after COPD exacerbations. Respir Res 2009, 10:45.
7. Mancini G.B., Etminan M., Zhang B., Levesque L.E., FitzGerald J.M., Brophy J.M. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol 2006, 47(12):2554-2560.
8. Ishida W., Kajiwara T., Ishii M., Fujiwara F., Taneichi H., Takebe N., et al. Decrease in mortality rate of chronic obstructive pulmonary disease (COPD) with statin use: a population-based analysis in Japan. Tohoku J Exp Med 2007, 212(3):265-273.
9. Blamoun A.I., Batty G.N., DeBari V.A., Rashid A.O., Sheikh M., Khan M.A. Statins may reduce episodes of exacerbation and the requirement for intubation in patients with COPD: evidence from a retrospective cohort study. Int J Clin Pract 2008, 62(9):1373-1378.
10. Standardization of spirometry, 1994 update. Am J Respir Crit Care Med 1995, 152(3):1107-1136. American Thoracic Society.
11. Jones P.W., Quirk F.H., Baveystock C.M., Littlejohns P. A self-complete measure of health status for chronic airflow limitation. The St. George's respiratory questionnaire. Am Rev Respir Dis 1992, 145(6):1321-1327.
12. Charlson M.E., Pompei P., Ales K.L., MacKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987, 40(5):373-383.
13. Dupont W.D., Plummer W.D. Power and sample size calculations. A review and computer program. Control Clin Trials 1990, 11(2):116-128.
14. McGhan R., Radcliff T., Fish R., Sutherland E.R., Welsh C., Make B. Predictors of rehospitalization and death after a severe exacerbation of COPD. Chest 2007, 132(6):1748-1755.
15. Frost F.J., Petersen H., Tollestrup K., Skipper B. Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins. Chest 2007, 131(4):1006-1012.
16. Almagro P., Calbo E., Ochoa de Echaguen A., Barreiro B., Quintana S., Heredia J.L., et al. Mortality after hospitalization for COPD. Chest 2002, 121(5):1441-1448.
17. Miravitlles M., Guerrero T., Mayordomo C., Sanchez-Agudo L., Nicolau F., Segu J.L. Factors associated with increased risk of exacerbation and hospital admission in a cohort of ambulatory COPD patients: a multiple logistic regression analysis. The EOLO Study Group. Respiration 2000, 67(5):495-501.
18. Patel I.S., Seemungal T.A., Wilks M., Lloyd-Owen S.J., Donaldson G.C., Wedzicha J.A. Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations. Thorax 2002, 57(9):759-764.
19. Aaron S.D., Vandemheen K.L., Clinch J.J., Ahuja J., Brison R.J., Dickinson G., et al. Measurement of short-term changes in dyspnea and disease-specific quality of life following an acute COPD exacerbation. Chest 2002, 121(3):688-696.
20. Donaldson G.C., Seemungal T.A., Bhowmik A., Wedzicha J.A. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002, 57(10):847-852.
21. Calverley P.M., Anderson J.A., Celli B., Ferguson G.T., Jenkins C., Jones P.W., et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007, 356(8):775-789.
22. Gan W.Q., Man S.F., Senthilselvan A., Sin D.D. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 2004, 59(7):574-580.
23. Sin D.D., Man S.F. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 2003, 107(11):1514-1519.
24. Hunninghake D.B. Cardiovascular disease in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005, 2(1):44-49.
25. Lee J.H., Lee D.S., Kim E.K., Choe K.H., Oh Y.M., Shim T.S., et al. Simvastatin inhibits cigarette smoking-induced emphysema and pulmonary hypertension in rat lungs. Am J Respir Crit Care Med 2005, 172(8):987-993.
26. Donaldson G.C., Seemungal T.A., Patel I.S., Bhowmik A., Wilkinson T.M., Hurst J.R., et al. Airway and systemic inflammation and decline in lung function in patients with COPD. Chest 2005, 128(4):1995-2004.
27. Sin D.D. Inhaled corticosteroids and mortality in COPD. Thorax 2006, 61(10):918.
28. Schonbeck U., Libby P. Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents?. Circulation 2004, 109(21 Suppl. 1):II18-26.
29. Barnes P.J. Future treatments for chronic obstructive pulmonary disease and its comorbidities. Proc Am Thorac Soc 2008, 5(8):857-864.
30. 1?. Respir Med 2009, 103(5):650-660.
31. Tashkin D.P., Celli B., Senn S., Burkhart D., Kesten S., Menjoge S., et al. 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008, 359(15):1543-1554.
32. Seemungal T.A., Donaldson G.C., Paul E.A., Bestall J.C., Jeffries D.J., Wedzicha J.A. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998, 157(5 Pt 1):1418-1422.
33. Jones P.W. Health status measurement in chronic obstructive pulmonary disease. Thorax 2001, 56(11):880-887.
34. Kiener P.A., Davis P.M., Murray J.L., Youssef S., Rankin B.M., Kowala M. Stimulation of inflammatory responses in vitro and in vivo by lipophilic HMG-CoA reductase inhibitors. Int Immunopharmacol 2001, 1(1):105-118.
35. Gray J., Edwards S.J., Lip G.Y. Comparison of sequential rosuvastatin doses in hypercholesterolaemia: a meta-analysis of randomised controlled trials. Curr Med Res Opin 2010, 26(3):537-547.
36. Rutten F.H., Zuithoff N.P., Hak E., Grobbee D.E., Hoes A.W. Beta-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch Intern Med 2010, 170(10):880-887.